

# Epigenetic and transcriptional signatures of stable versus plastic differentiation of proinflammatory $\gamma\delta$ T cell subsets

Nina Schmolka<sup>1,5</sup>, Karine Serre<sup>1,5</sup>, Ana R Grosso<sup>1</sup>, Margarida Rei<sup>1,2</sup>, Daniel J Pennington<sup>2</sup>, Anita Q Gomes<sup>1,3</sup> & Bruno Silva-Santos<sup>1,4</sup>

Two distinct subsets of  $\gamma\delta$  T cells that produce interleukin 17 (IL-17) (CD27<sup>-</sup>  $\gamma\delta$  T cells) or interferon- $\gamma$  (IFN- $\gamma$ ) (CD27<sup>+</sup>  $\gamma\delta$  T cells) develop in the mouse thymus, but the molecular determinants of their functional potential in the periphery remain unknown. Here we conducted a genome-wide characterization of the methylation patterns of histone H3, along with analysis of mRNA encoding transcription factors, to identify the regulatory networks of peripheral IFN- $\gamma$ -producing or IL-17-producing  $\gamma\delta$  T cell subsets *in vivo*. We found that CD27<sup>+</sup>  $\gamma\delta$  T cells were committed to the expression of *Ifng* but not *Il17*, whereas CD27<sup>-</sup>  $\gamma\delta$  T cells displayed permissive chromatin configurations at loci encoding both cytokines and their regulatory transcription factors and differentiated into cells that produced both IL-17 and IFN- $\gamma$  in a tumor microenvironment.

$\gamma\delta$  T cells have emerged as key providers of interleukin 17 (IL-17) in various models of infection, inflammation and autoimmunity<sup>1–6</sup>. Antibody-mediated or genetic depletion of  $\gamma\delta$  T cells greatly reduces disease severity in IL-17-driven models of chronic inflammation<sup>1–4,7</sup>. Those results notwithstanding, many reports have made a compelling case for  $\gamma\delta$  T cells as major producers of interferon- $\gamma$  (IFN- $\gamma$ ) in both mice and humans<sup>8</sup>, which has been a foundation for clinical trials targeting these lymphocytes in cancer immunotherapy<sup>9</sup>. Given the dual ability of  $\gamma\delta$  T cells to produce IL-17 and IFN- $\gamma$ , published work has aimed to identify markers associated with functional attributes of mouse  $\gamma\delta$  T cells<sup>10–13</sup>. Expression of the costimulatory receptor CD27 segregates IL-17-producing (CD27<sup>-</sup>)  $\gamma\delta$  T cells and IFN- $\gamma$ -producing (CD27<sup>+</sup>)  $\gamma\delta$  T cells in both naive and *Plasmodium*-infected C57BL/6 mice<sup>10</sup>. Moreover, the chemokine receptor CCR6, which is expressed exclusively on CD27<sup>-</sup>  $\gamma\delta$  T cells, constitutes an additional marker for IL-17<sup>+</sup>  $\gamma\delta$  T cells<sup>13,14</sup>.

Both CD27<sup>+</sup> and CD27<sup>-</sup>  $\gamma\delta$  T cell subsets show spontaneous cytokine secretion after activation, in contrast to the delayed differentiation of conventional CD4<sup>+</sup> T cells of the T<sub>H</sub>1 or T<sub>H</sub>17 subset of helper T cells<sup>15</sup>. That finding is highlighted by the observation that 30–40% of peripheral  $\gamma\delta$  T cells freshly isolated from naive mice produce either IL-17 or IFN- $\gamma$  after 3 h of restimulation *in vitro*<sup>10</sup>. Those functionally mature  $\gamma\delta$  T cell subsets are also found in the thymus as early as the embryonic stages of mouse development<sup>10–12,16</sup>. Moreover, the expression of genes linked to the production of IL-17 or IFN- $\gamma$  segregates with particular  $\gamma\delta$  thymocyte subsets<sup>17</sup>. However, the epigenetic ‘landscape’ of  $\gamma\delta$  T cells, which, as for CD4<sup>+</sup> T cells<sup>18,19</sup>, probably dynamically controls the expression of genes encoding signature

cytokines and their transcriptional regulators, remains unknown. Among other epigenetic mechanisms, methylation of histone H3 at Lys4 (H3K4me) or Lys27 (H3K27me) controls the accessibility of genes for the transcriptional machinery and thereby regulates cell fate<sup>19</sup>. Notably, the advent of deep (massive) sequencing, coupled to chromatin immunoprecipitation (ChIP), has allowed the genome-wide characterization of H3K4- and H3K27-methylation patterns in various cell types, including CD4<sup>+</sup> helper T cell subsets that were differentiated *in vitro*<sup>18</sup>.

To gain insight into the epigenetic regulation of  $\gamma\delta$  T cell subsets, we conducted genome-wide profiling of active dimethylated H3K4 (H3K4me2) and repressive trimethylated H3K4 (H3K4me3) modifications, complemented with analysis of additional chromatin marks (H3K36me3 and H3 acetylation) and transcriptional quantification of CD27<sup>+</sup>  $\gamma\delta$  ( $\gamma\delta$ 27<sup>+</sup>) T cell or CD27<sup>-</sup>  $\gamma\delta$  ( $\gamma\delta$ 27<sup>-</sup>) T cell subsets isolated from secondary lymphoid organs and compared those with the histone modifications and mRNA abundance in T<sub>H</sub>1 or T<sub>H</sub>17 CD4<sup>+</sup> T cells differentiated *in vitro*. Our results constitute a public resource describing the epigenomes of  $\gamma\delta$ 27<sup>+</sup> and  $\gamma\delta$ 27<sup>-</sup> T cells and their effect on key transcriptional regulators of differentiation, and provide new insights on the peripheral functions of thymus-derived  $\gamma\delta$  T cell subsets.


## RESULTS

### Genome-wide analysis of H3 methylation in $\gamma\delta$ T cell subsets

To obtain a global profiling of chromatin modifications in  $\gamma\delta$  T cell subsets (isolated from pooled lymph nodes and spleen), we analyzed those cells by ChIP with antibody to H3K4me2 (anti-H3K4me2) and

<sup>1</sup>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. <sup>2</sup>Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK. <sup>3</sup>Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, Portugal. <sup>4</sup>Instituto Gulbenkian de Ciência, Oeiras, Portugal. <sup>5</sup>These authors contributed equally to this work. Correspondence should be addressed to B.S.-S. (bssantos@fm.ul.pt) or A.Q.G. (anitagomes@fm.ul.pt).

Received 7 June; accepted 6 August; published online 1 September 2013; doi:10.1038/ni.2702



**Figure 1** Genome-wide histone H3 methylation in subsets of  $\gamma\delta$  T cells and CD4<sup>+</sup> helper T cells. **(a)** ChIP-seq quantification of genes associated with H3K4me2 or H3K27me3 alone or H3K4me2 and H3K27me3 together (Both) in the total pool of  $\gamma\delta 27^+$  T cells, CCR6<sup>+</sup>  $\gamma\delta 27^-$   $\gamma\delta$  T cells and CD4<sup>+</sup> T<sub>H1</sub> and T<sub>H17</sub> cells, in the following genomic regions: distal promoter (–4 kb to –1 kb upstream of the transcription start site) plus gene (Dist prom + gene); proximal promoter (–1 kb to +1 kb around the transcription start site; Prox prom); internal gene body (+1 kb from the start site to end of gene; Int body); and the gene (proximal promoter + internal gene body; Gene). **(b)** ChIP-seq quantification of genes associated with histone modifications as in **a** in each of the four T cell subsets in **a**. **(c)** Overlap of genes associated with histone modifications in the four T cell subsets in **a**, presented as Venn diagrams. **(d)** Frequency of genes with differences in modification in  $\gamma\delta 27^+$  T cells versus (vs)  $\gamma\delta 27^-$  T cells (left) or T<sub>H1</sub> cells versus T<sub>H17</sub> cells (right) among those with H3K4me2 or H3K27me3 modifications or both H3K4me2 and H3K27me3 modifications. Samples were analyzed a second time to ensure the technical reproducibility of ChIP-seq results; results were confirmed by ChIP-qPCR analysis of biological duplicates. Data are from one experiment with cells pooled from eight mice.

anti-H3K27me3, followed by deep sequencing (ChIP-seq). As reference, we differentiated CD4<sup>+</sup> T<sub>H1</sub> and T<sub>H17</sub> subsets by standard *in vitro* protocols and subjected those to the same ChIP-seq analysis. This confirmed published observations of T<sub>H1</sub>-biased *Ifng* expression and H3K4me2 marks in the *Ifng* locus<sup>18</sup>, which contrasted with the expression and H3K4me2 modifications of *Il17a* in T<sub>H17</sub> cells (Supplementary Fig. 1).

We subjected the ChIP-seq data to in-depth bioinformatics analysis. We used three different ‘peak-calling’ tools to detect enrichment for histone-modification density and assigned only peaks consistently retrieved by all three methods. We first examined the H3-methylation patterns, across the entire genome, in the total pool of T cell subsets under study:  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells, and T<sub>H1</sub> and T<sub>H17</sub> cells. This revealed that the vast majority (95%) of all H3-modified genes (in the total pool of T cell subsets) displayed the H3K4me2 or H3K27me3 marks in the promoter-proximal region (1 kilobase (kb) upstream and downstream of transcription start site); we observed only a small increase in H3 modifications when we also considered the distal promoter region (Fig. 1a). High proportions of H3-modified genes were associated with H3K4me2 alone (50%) or with both H3K4me2 or H3K27me3 marks (27%), with similar patterns observed for all four T cell subsets (Fig. 1b). A smaller fraction of H3-modified genes (<18%) displayed repressive H3K27me3 marks alone (Fig. 1b), with 4% (883 genes) of all H3-modified genes displaying only H3K27me3 marks concomitantly in all four T cell subsets (Fig. 1c). Quantitative analysis of the genes marked by H3K4me2 alone, H3K27me3 alone or both H3K4me2 and H3K27me3 revealed that from an epigenetic perspective, the  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cell subsets generated *in vivo* were as distinct from each other as were the CD4<sup>+</sup> T<sub>H1</sub> and T<sub>H17</sub> cells subsets polarized *in vitro* (Fig. 1d).

We next focused our analysis on the two  $\gamma\delta$  T cell subsets and compared the H3-methylation densities of  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells. On the basis of quantitative algorithms, a total of 10,581 genes had a difference in the abundance of either H3K4me2 or H3K27me3 marks (Fig. 2a,b). Those marks were located in the promoter-proximal region for 64% of all genes with a difference in H3 modification in  $\gamma\delta 27^+$  T cells versus  $\gamma\delta 27^-$  T cells (Fig. 2a).


Selective inspection of the epigenetically regulated genes in  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cell subsets indicated that genes linked to ( $\gamma\delta$ ) T cell

development (such as *Bcl11b*, *Id3* or *Etv5*)<sup>17</sup> displayed almost identical histone marking in both subsets (Fig. 2c). In contrast, genes encoding effector cytokines (*Il17a*, *Il17f* and *Il22*) showed substantially more enrichment for permissive H3K4me2 marks in  $\gamma\delta 27^-$  T cells than in  $\gamma\delta 27^+$  T cells (Fig. 2c). These epigenetic profiles suggested that  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells share an early developmental program but diverge during functional differentiation into cytokine-producing subsets.

#### Additional targets in the differentiation of $\gamma\delta$ T cell subsets

We next examined the full H3K4me2-H3K27me3 epigenome of  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells (Supplementary Table 1) to identify genes encoding molecules involved in their differentiation. *Il17a*, *Il17f* and *Il22* were among the genes with the greatest difference between the two subsets in H3 modification, and all showed more enrichment for active H3K4me2 marks in  $\gamma\delta 27^-$  T cells than in  $\gamma\delta 27^+$  T cells (Supplementary Table 2). We noted the same pattern for *Ccr6* (which encodes the chemokine receptor CCR6) and *Il1r1* and *Il23r* (which encode cytokine receptors) (Supplementary Table 2), all known to be expressed in  $\gamma\delta 27^-$  cells<sup>1,13,14,20</sup>. Those results notwithstanding, the 25 genes with the greatest difference in modification in  $\gamma\delta 27^+$  T cells versus  $\gamma\delta 27^-$  T cells represented previously unknown targets for the development and function of  $\gamma\delta$  T cells (Supplementary Table 2). *Dock8* and *Dkk3* displayed active H3K4me2 marks in  $\gamma\delta 27^-$  T cells but not in  $\gamma\delta 27^+$  T cells. The guanine-exchange factor DOCK8 is a signaling adaptor that controls the survival and function of CD8<sup>+</sup> T cells<sup>21</sup> and activation of B cells<sup>22</sup>. Moreover, *DOCK8* mutation in humans causes severe combined immunodeficiency associated with high susceptibility to infection<sup>21,22</sup>. *DKK3* is a glycoprotein that modulates Wnt signaling and has a regulatory function in CD8<sup>+</sup> T cells<sup>23</sup>.

While our analysis revealed many signaling mediators and transcription factors of unknown function in  $\gamma\delta$  T cells (or T cells in general), various candidates were among the proteins with receptor activity (Supplementary Table 2): the costimulatory receptor SLAMF1 (CD150), which controls the development of natural killer (NK) T cells<sup>24</sup> and promotes inflammation in a mouse model of colitis<sup>25</sup>; the scavenger receptor SCARF1, which recognizes and triggers innate immune responses to fungi<sup>26</sup>; EPHB2, which orchestrates



**Figure 2** Peripheral  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells display distinct genome-wide histone H3 methylation patterns. **(a)** ChIP-seq quantification of genes associated with differences in H3K4me2 or H3K27me3 histone modifications in the full gene or the proximal promoter region (as defined in **Fig. 1a**) in peripheral  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells. **(b)** Histone-modification profiles of genes with a greater abundance of H3K4me2 or H3K27me3 in  $\gamma\delta 27^+$  or  $\gamma\delta 27^-$  T cells; the 5' and 3' ends are 'unscaled', and the remainder of the gene is rescaled to 2 kb; long gray vertical lines correspond to gene regions along horizontal axes; gray shading indicates error bars. TSS, transcription start site. **(c)** Quantification ( $\log_{10}$ -transformed) of H3K4me2 and H3K27me3 modifications of genes linked to T cell development (top) or of signature cytokine-encoding genes (bottom), in  $\gamma\delta 27^+$  or  $\gamma\delta 27^-$  T cells. Reproducibility and ChIP-qPCR, as in **Figure 1**. Data are from one experiment with cells pooled from eight mice.

the crosstalk between thymocytes and thymic epithelial cells and thus affects early T cell development<sup>27</sup>; Flt1, which binds vascular endothelial growth factor A and costimulates IFN- $\gamma$  production<sup>28</sup>; and OX40 (TNFRSF4), a costimulator of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as well as NK and NKT cells<sup>29</sup>, although its role in the activation of  $\gamma\delta$  T cells remains unclear. The only chemokine receptor-encoding gene other than *Ccr6* with substantially different modification in  $\gamma\delta 27^-$  T cells versus  $\gamma\delta 27^+$  T cells was *Ccr1* (**Supplementary Table 2**); CCR1 has been linked to the migration of macrophages and neutrophils<sup>30</sup> but not T cells.

Six of those eight candidates also had a difference in H3K4me2 modification in thymic  $\gamma\delta 27^-$  T cells versus  $\gamma\delta 27^+$  T cells (**Supplementary Fig. 2**). Except for *Ccr1*, those genes had a greater abundance of H3K4me2 marks in peripheral  $\gamma\delta$  T cell subsets than in thymic  $\gamma\delta$  T cell subsets (**Supplementary Fig. 2**). This suggested that the epigenetic segregation of the gene-expression programs of  $\gamma\delta 27^-$  and  $\gamma\delta 27^+$  T cells starts in the thymus but is further consolidated as cells continue to mature in the periphery.

We did preliminary analysis of the expression of *Dkk3* and *Slamf1* on  $\gamma\delta$  T cells and assessed the effect of their deletion on the differentiation and function of  $\gamma\delta$  T cells.  $\gamma\delta 27^-$  T cells showed considerable enrichment for *Dkk3* mRNA and SLAMF1 protein relative to their abundance in  $\gamma\delta 27^+$  T cells (**Fig. 3a,b**). SLAMF1 was coexpressed with CCR6 in the thymus and in the periphery (**Fig. 3b**) and thus constitutes an additional marker for the CD27-CCR6<sup>+</sup>  $\gamma\delta$  T cell subset<sup>10,13,14</sup>. Whereas we observed no difference between *Slamf1*<sup>-/-</sup> and wild-type mice in their production of IL-17, *Dkk3*<sup>-/-</sup> mice displayed greater frequencies of peripheral IL-17-producing  $\gamma\delta 27^-$  T cells than did wild-type mice (**Fig. 3c**). In contrast, IL-17 expression was normal in *Dkk3*<sup>-/-</sup> T<sub>H</sub>17 cells (**Fig. 3d**), and IFN- $\gamma$  production was not altered in *Dkk3*<sup>-/-</sup>  $\gamma\delta 27^+$  or T<sub>H</sub>1 cells (data not shown). These data suggested a role for DKK3 in selectively regulating IL-17 production in  $\gamma\delta 27^-$  T cells. Thus, this analysis has provided a set of potential additional regulators of the differentiation and activation of  $\gamma\delta$  T cells, some of which may also be shared with CD4<sup>+</sup> helper T cells (**Supplementary Table 2**).


### Epigenetic control of cytokine expression in $\gamma\delta$ T cell subsets

We next focused on the epigenetic regulation of genes encoding signature cytokines in the two  $\gamma\delta$  T cell subsets. In contrast to *Il17a*, *Il17f* and *Il22* (**Supplementary Table 2**), *Ifng* did not show a difference in H3 methylation in  $\gamma\delta 27^+$  T cells versus  $\gamma\delta 27^-$  T cells (**Supplementary Table 1**). Individual ChIP-seq profiles showed that *Il17a* (**Fig. 4a**) and *Il17f* and *Il22* (**Supplementary Fig. 3a**) accumulated many active H3K4me2 marks in  $\gamma\delta 27^-$  T cells but not in  $\gamma\delta 27^+$  T cells, whereas the *Ifng* locus displayed H3K4me2 marks in both  $\gamma\delta$  cell subsets (**Fig. 4a**). ChIP followed by quantitative PCR (ChIP-qPCR) with primers for the respective promoters and other known regulatory conserved non-coding sequences<sup>31-33</sup> confirmed accumulation of active H3K4me2 marks in the *Ifng* locus in both  $\gamma\delta 27^+$  T cells and  $\gamma\delta 27^-$  T cells in the periphery (**Fig. 4b** and **Supplementary Fig. 3b,c**) and in the thymus (**Fig. 4c**). The segregation of repressive H3K27me3 marks in  $\gamma\delta 27^+$  T cells versus  $\gamma\delta 27^-$  T cells was less obvious at loci encoding the signature cytokines, by both ChIP-seq (**Fig. 4a** and **Supplementary Fig. 3a**) and ChIP-qPCR (**Supplementary Fig. 4**).

We also investigated additional histone modifications that associate with gene expression. Acetylation of histone H3 has been linked to the expression of genes important for the differentiation of helper T cells<sup>31,34</sup>. ChIP-qPCR of  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells, with primers specific for the *Ifng* and *Il17a* promoters, showed the presence of acetylated H3 marks at the *Il17a* locus exclusively in  $\gamma\delta 27^-$  cells, while these permissive marks were of almost identical abundance at the *Ifng* locus in both  $\gamma\delta$  T cell subsets (**Fig. 4d**).

To evaluate the effect of those histone-modification patterns on the expression of cytokine-encoding genes, we measured *Ifng* and *Il17a* mRNA by reverse transcription followed by quantitative PCR (quantitative RT-PCR). Consistent with the epigenetic data, *Il17a* had ~700-fold higher expression in peripheral  $\gamma\delta 27^-$  T cells than in peripheral  $\gamma\delta 27^+$  T cells, while *Ifng* had ~10-fold higher expression in

**Figure 3** DKK3 and SLAMF1 are molecular determinants of  $\gamma\delta 27^-$  T cells. (a) Quantitative RT-PCR analysis of *Dkk3* expression in *ex vivo* CD4<sup>+</sup> T cells (Naive splenic CD4<sup>+</sup>,  $\gamma\delta 27^+$  T cells and  $\gamma\delta 27^-$  T cells (sorted from peripheral organs) and CD4<sup>+</sup> T<sub>H1</sub> and T<sub>H17</sub> cells generated *in vitro* (all sorted from C57BL/6 mice); results are presented relative to those of *Actb* (control gene). \**P* < 0.05 (Mann-Whitney two-tailed test).




(b) Surface expression of SLAMF1 (CD150), CD27 and CCR6 on total  $\gamma\delta$  T cells from cutaneous lymph nodes (LN (cut); left) and thymus (right), assessed by flow cytometry. Numbers in quadrants indicate percent cells in each throughout. (c) Intracellular staining of IFN- $\gamma$  and IL-17A in  $\gamma\delta 27^-$  cells isolated from groups of C57BL/6 wild-type (WT), *Dkk3*<sup>-/-</sup> and *Slamf1*<sup>-/-</sup> mice (left), and frequency of IL-17<sup>+</sup>  $\gamma\delta 27^-$  T cells in those mouse strains (right). (d) Intracellular staining of IFN- $\gamma$  and IL-17A in T<sub>H17</sub> cells differentiated *in vitro* from CD4<sup>+</sup> T cells isolated from wild-type, *Dkk3*<sup>-/-</sup> and *Slamf1*<sup>-/-</sup> mice. Each symbol (a,c, right) represents an individual experiment. Data are from four experiments with cells pooled from four mice in each (a) or two (*Slamf1*<sup>-/-</sup>), three (*Dkk3*<sup>-/-</sup>) or seven (wild-type) experiments with cells pooled from four mice in each (c) or are representative of three independent experiments with two or three mice in each (b) or two independent experiments with one mouse per strain in each (d).

$\gamma\delta 27^+$  T cells than in  $\gamma\delta 27^-$  T cells (Fig. 4e). Moreover, *Il17f* and *Il22* were also overexpressed in  $\gamma\delta 27^-$  T cells (Supplementary Fig. 3d). We also found similar differences for thymic  $\gamma\delta$  T cell subsets, in which the difference in expression was ~2-fold for *Ifng* and >200-fold for *Il17a* (Fig. 4f) and *Il22* (data not shown). Of note, in the thymus, *Ifng* and *Il17a* transcripts were expressed only in  $\gamma\delta$  T cells and were almost undetectable in  $\alpha\beta$  thymocytes (Fig. 4f). Both *Ifng* and *Il17a* were expressed in CD25<sup>+</sup>  $\gamma\delta$  thymocytes, which represent a common progenitor population for both  $\gamma\delta 27^-$  and  $\gamma\delta 27^+$  T cells<sup>10</sup>, followed by further upregulation of *Ifng* in  $\gamma\delta 27^+$  T cells and of *Il17a* in  $\gamma\delta 27^-$  thymocytes (Fig. 4f). These data demonstrated that the expression


of genes encoding signature cytokines in  $\gamma\delta$  T cells is epigenetically patterned in the thymus and is sustained in peripheral  $\gamma\delta$  T cell subsets and revealed a distinct degree of polarization toward T<sub>H1</sub>-like or T<sub>H17</sub>-like effector function among  $\gamma\delta$  T cell subsets.

**Epigenetic patterning of T<sub>H1</sub> versus T<sub>H17</sub> factors in  $\gamma\delta$  T cells**

We next analyzed our ChIP-seq data for (mostly transcription) factors that have been linked to the differentiation of T<sub>H1</sub> or T<sub>H17</sub> cells<sup>15</sup>



**Figure 4** Epigenetic and transcriptional patterning of *Ifng* and *Il17a* in  $\gamma\delta$  T cell subsets. (a) ChIP-seq analysis of H3K4me2 (green) and H3K27me3 (black) modifications on *Ifng* and *Il17a* in peripheral  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells; below, chromosome (Chr) locations and exon positions (black boxes). (b,c) ChIP-qPCR analysis of H3K4me2 modifications on *Ifng* (promoter (Prom) and conserved noncoding sequence -34 regions (CNS-34)) and *Il17a* (promoter (Prom) and conserved noncoding sequence +5 regions (CNS+5)) in peripheral (b) or thymic (c)  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells; results are presented relative to total H3. (d) ChIP-qPCR analysis of total acetylated histone H3 in the promoter regions of *Ifng* or *Il17a* in peripheral  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells (presented as in c). (e) Quantitative RT-PCR analysis of the expression of *Ifng* and *Il17a* in CD4<sup>+</sup>,  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells from pooled spleen and lymph nodes of C57BL/6 mice (e) and in CD4<sup>+</sup>CD8<sup>+</sup> double-positive (DP) and CD4<sup>+</sup> single-positive (SP CD4) thymocytes of the  $\alpha\beta$  T cell lineage and CD25<sup>+</sup>CD27<sup>+</sup> ( $\gamma\delta 25^+$ ), CD25<sup>-</sup> $\gamma\delta 27^+$  and CD25<sup>-</sup> $\gamma\delta 27^-$  thymocytes of the  $\gamma\delta$  T cell lineage (e), presented relative to *Actb* expression. Each symbol (e,f) represents an individual experiment. \**P* < 0.05 and \*\**P* < 0.001 (Mann-Whitney two-tailed test). Data are from one experiment with cells pooled from eight mice (a-d) or eight independent experiments with cells pooled from four mice in each (e,f; mean and s.d. in b-d).



**Figure 5** Permissive histone H3 methylation patterns associate with transcription of  $T_H1$ - and  $T_H17$ -related factors in  $\gamma\delta$  T cell subsets. (a) ChIP-seq analysis of H3K4me2 (green) and H3K27me3 (black) modifications on genes encoding  $T_H1$ -related factors (*Tbx21*, *Eomes*, *Hlx*; left) and  $T_H17$ -related factors (*Rorc*, *Batf*, *Blk*; right) in peripheral  $\gamma\delta27^+$  and  $\gamma\delta27^-$  T cells (below plots, as in Fig. 4a). (b) Quantification ( $\log_{10}$ -transformed) of gene-specific H3K4me2 modifications on genes in  $\gamma\delta27^+$  T cells and  $\gamma\delta27^-$  T cells for genes grouped as  $T_H1$ - and  $T_H17$ -related factors (top left), genes linked to  $\gamma\delta$  T cell development (top right), genes associated with alternative effector cell types (bottom left) and housekeeping reference or survival genes (bottom right). (c) ChIP-qPCR analysis of H3K36me3 modifications on *Tbx21*, *Eomes*, and *Rorc* in  $\gamma\delta27^+$  and  $\gamma\delta27^-$  T cells, presented relative to the abundance of total H3. (d) Quantitative RT-PCR analysis of genes encoding  $T_H1$ -related factors (top) and  $T_H17$ -related factors (bottom) on *ex vivo*  $CD4^+$  T cells and  $\gamma\delta27^+$  and  $\gamma\delta27^-$  T cells (derived from peripheral T cells) and  $CD4^+$   $T_H1$  and  $T_H17$  cells generated *in vitro*, presented relative to *Actb* expression. NS, non significant; \* $P < 0.05$  (Mann-Whitney two-tailed test). (e) Expression of  $T_H1$ - and  $T_H17$ -associated genes (from data in d) in  $\gamma\delta27^+$  T cells versus  $\gamma\delta27^-$  T cells (top) or  $CD4^+$   $T_H1$  cells versus  $T_H17$  cells (bottom). Each symbol (d,e) represents an individual experiment (d) or the mean of the data in d (e). Data are from one experiment with cells pooled from eight mice (a–c) or five independent experiments with cells pooled from four mice in each (d,e; mean and s.d. in c,e).

or, in some instances, specifically to the differentiation of cytokine-producing  $\gamma\delta$  T cells<sup>35,36</sup>. For simplicity, here we have designated the regulators of IFN- $\gamma$  or IL-17 production (in either  $CD4^+$  or  $\gamma\delta$  T cells) ‘ $T_H1$  factors’ or ‘ $T_H17$  factors’, respectively. Examination of individual ChIP-seq profiles (Fig. 5a) or their global activity (Fig. 5b) revealed  $T_H17$  polarization of  $\gamma\delta27^-$  T cells but not of  $\gamma\delta27^+$  T cells, indicated by the accumulation of permissive H3K4me2 marks in genes encoding differentiation factors, such as *Rorc*, *Rora* or *Batf* (Fig. 5a,b), as well as in the cytokine receptor-encoding genes *Il1r1* and *Il23r1*<sup>20</sup> and the chemokine receptor-encoding gene *Ccr6* (ref. 13) (Supplementary Fig. 5a). Moreover, *Rorc* and *Blk* (Fig. 5a) and *Maf* and *Irf4* (data not shown) displayed repressive H3K27me3 modifications in  $\gamma\delta27^+$  T cells but not in  $\gamma\delta27^-$  T cells. In contrast, most genes encoding  $T_H1$ -differentiation factors (such as *Tbx21*, *Eomes* and *Hlx*) were positively marked by H3K4me2 in both  $\gamma\delta$  T cell subsets, and some (*Eomes* and *Hlx*) also displayed substantial repressive H3K27me3 modification in both  $\gamma\delta$  T cell subsets (Fig. 5a). As reference, genes encoding molecules associated with cell survival, the development of  $\gamma\delta$  T cells or alternative T cell effector functions did not show a difference in H3 modification in the two  $\gamma\delta$  T cell subsets (Fig. 5b and data not shown).

To further document the epigenetic regulation of important transcription regulators in  $\gamma\delta$  T cell subsets, we analyzed the H3K36me3 marking of the *Tbx21*, *Eomes* and *Rorc* loci. H3K36me3 modifications, which accumulate at the 3' end of genes, correlate with transcriptional

activity in intron-containing genes<sup>37</sup>. The two  $\gamma\delta$  T cell subsets showed a difference of less than threefold in the H3K36me3 marking of *Tbx21* or *Eomes*, whereas the *Rorc* locus had more than tenfold more H3K36me3 marking in  $\gamma\delta27^-$  T cells than in  $\gamma\delta27^+$  T cells (Fig. 5c). The difference in the patterning of  $T_H1$  or  $T_H17$  factors in peripheral  $\gamma\delta$  T cell subsets extended to the transcriptional level, as by quantitative RT-PCR analysis we estimated the abundance of *Rorc* transcripts was ~600-fold greater in  $\gamma\delta27^-$  T cells than in  $\gamma\delta27^+$  T cells, whereas the abundance of *Tbx21* and *Eomes* was only slightly (four- to sixfold) greater in  $\gamma\delta27^+$  T cells (Fig. 5d). Furthermore, H3K4me2 modifications of the *Ifng* promoter in  $\gamma\delta27^+$  T cells were similar in wild-type and *Tbx21*<sup>-/-</sup> mice (Supplementary Fig. 6), and *Tbx21*<sup>-/-</sup> mice had a substantial proportion of IFN- $\gamma$ -producing  $\gamma\delta$  T cells (Supplementary Fig. 7a,b). In contrast, *Rorc*<sup>-/-</sup> mice lacked the CCR6<sup>+</sup> ( $\gamma\delta27^-$ ) T cell subset in both the thymus and spleen (Supplementary Fig. 7c) and did not express IL-17A in total  $\gamma\delta$  T cells (Supplementary Fig. 7d).

Although the expression of many  $T_H1$  factors versus that of  $T_H17$  factors segregated with the two peripheral  $\gamma\delta$  T cell subsets (Fig. 5e), the transcriptional polarization was much stronger for the  $T_H17$  program (Fig. 5d,e). That was consistent with the accumulation of repressive H3K27me3 marks at  $T_H17$ -related loci, such as *Rorc*, *Blk* and *Maf* (Fig. 5a and data not shown), in  $\gamma\delta27^+$  T cells. Of note, the expression of *Rorc*, *Rora* and *Maf* was higher in  $\gamma\delta27^-$  T cells *ex vivo* than in  $T_H17$  cells generated *in vitro* (Fig. 5d), and overall there was better segregation of  $T_H17$  transcription factors in  $\gamma\delta$  T cells than in  $CD4^+$  helper


**Figure 6** Differentiation of IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$ 27<sup>-</sup> cells *in vitro* and *in vivo*.

(a) Intracellular staining of IFN- $\gamma$  and IL-17A in  $\gamma\delta$ 27<sup>+</sup> and  $\gamma\delta$ 27<sup>-</sup> T cells isolated from pooled spleen and lymph nodes and stimulated *in vitro* for 48 h in the presence of IL-1 $\beta$  plus IL-23 or standard T<sub>H</sub>1- or T<sub>H</sub>17-polarizing conditions. ND, not determined (lack of cell viability; **Supplementary Fig. 8**).

(b) Frequency of IL-17A<sup>+</sup>IFN- $\gamma$ <sup>+</sup> cells in the cultures in **a**, normalized to the proportion of live cells (**Supplementary Fig. 8**).

(c) Intracellular IFN- $\gamma$  and IL-17A (right) in total  $\gamma\delta$  T cells (gated at left) from peritoneal exudates obtained at 2 or 6 weeks of the development of ID8 tumors in C57BL/6 mice. Numbers adjacent to outlined areas indicate percent  $\gamma\delta$  T cells (right column), or IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells (top left), IL-17A<sup>+</sup>  $\gamma\delta$  T cells (bottom right) or IFN- $\gamma$ <sup>+</sup>IL-17A<sup>+</sup>  $\gamma\delta$  T cells (top right; all left column). (d) Overlay of the surface staining of CD27 on IL-17A<sup>+</sup>, IL-17A<sup>+</sup>IFN- $\gamma$ <sup>+</sup> or IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells from peritoneal exudates at 6 weeks of ID8 tumor development (as in c). (e) Frequency of IL-17A<sup>+</sup>IFN- $\gamma$ <sup>+</sup> cells among CD27<sup>-</sup>  $\gamma\delta$  T cells (as in c,d).

Each symbol (b,e) represents an individual experiment. \**P* < 0.05 and \*\**P* < 0.01 (Mann-Whitney two-tailed test). Data are representative of four to six independent experiments (a,b) or two independent experiments with four mice in each (c–e).



T cell subsets (**Fig. 5e**). These data documented distinct epigenetic patterning and transcriptional regulation of T<sub>H</sub>1 factors versus T<sub>H</sub>17 factors in  $\gamma\delta$  T cell subsets and showed that both  $\gamma\delta$ 27<sup>+</sup> and  $\gamma\delta$ 27<sup>-</sup> T cells had T<sub>H</sub>1 factors epigenetically primed for expression.

**Stable versus plastic differentiation of  $\gamma\delta$  T cell subsets**

In line with the epigenetic status of *Ifng* and the genes encoding T<sub>H</sub>1 factors described above,  $\gamma\delta$ 27<sup>-</sup> T cells stimulated *in vitro* are reported to produce both IL-17 and IFN- $\gamma$ <sup>10</sup>. To further explore the conditions that trigger IFN- $\gamma$  production in those cells, we established short-term cultures of highly purified  $\gamma\delta$ 27<sup>-</sup> or  $\gamma\delta$ 27<sup>+</sup> T cells in cytokine-defined media.  $\gamma\delta$ 27<sup>-</sup> T cells responded to IL-1 $\beta$  and IL-23 by acquiring IFN- $\gamma$  production, which resulted in a sizeable population of cells that produced both IL-17 and IFN- $\gamma$  (**Fig. 6a,b**). The differentiation of  $\gamma\delta$ 27<sup>-</sup> T cells into cells that produced both IL-17 and IFN- $\gamma$  was negligible under T<sub>H</sub>17-differentiation conditions (**Fig. 6a,b**), whereas T<sub>H</sub>1-differentiation conditions did not support the survival of  $\gamma\delta$ 27<sup>-</sup> T cells (**Supplementary Fig. 8**). Furthermore,  $\gamma\delta$ 27<sup>+</sup> T cells stably and exclusively produced IFN- $\gamma$ , even under T<sub>H</sub>17 conditions (**Fig. 6a**). Of note, stimulation with IL-1 $\beta$  and IL-23 resulted in the death of  $\gamma\delta$ 27<sup>+</sup> cells (**Supplementary Fig. 8**), consistent with their lack of expression of the corresponding receptors (**Supplementary Fig. 5**).

Finally, we sought to determine if the plasticity of  $\gamma\delta$ 27<sup>-</sup> T cells was detectable *in vivo*. To investigate whether the systemic immune response to infection could drive the differentiation of IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells, we set up *in vivo* infection models based on four distinct types of microorganisms that elicit  $\gamma\delta$  T cell responses<sup>10,20</sup>: a parasite (*Plasmodium berghei*), a virus (murid herpes virus 4), a bacterium (*Mycobacterium avium*) and a fungus (*Candida albicans*). We isolated cells from the spleen and lymph nodes at the peak of each  $\gamma\delta$  T cell response. However, we did not observe substantial populations of IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells in these acute infection models (**Supplementary Fig. 9**).

We reasoned that a strong local inflammatory response might be necessary for the differentiation of IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells *in vivo*.

We therefore transplanted an ovarian cancer cell line (ID8) known to produce a highly inflammatory microenvironment<sup>38</sup> into the peritoneal cavity of mice and monitored the growth of ID8 tumor cells (transfected with a plasmid bearing a luciferase reporter-encoding gene) by bioimaging techniques<sup>38</sup> (data not shown). We observed the accumulation of a sizeable population of IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells after tumor growth (at 6 weeks; **Fig. 6c**). Those IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup> T cells were CD27<sup>-</sup>, unlike the IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells (**Fig. 6d**). In fact, IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup> cells constituted up to 30% of the  $\gamma\delta$ 27<sup>-</sup> T cell subset present in the tumor-bearing peritoneal cavity (**Fig. 6e**). In contrast,  $\gamma\delta$ 27<sup>+</sup> T cells remained exclusive producers of IFN- $\gamma$  (**Fig. 6d**). These data demonstrated that the plasticity of  $\gamma\delta$ 27<sup>-</sup> T cells, which is in contrast to the stable phenotype of the  $\gamma\delta$ 27<sup>+</sup> T cells, was triggered under specific local inflammatory conditions and may thus contribute to their function *in vivo*.

**DISCUSSION**

Epigenetic mechanisms ensure the autonomous maintenance of lineage phenotype in differentiated cells, even through mitotic divisions. Methylation patterns of active H3K4 and repressive H3K27 have been shown to affect the functional (in)stability of effector CD4<sup>+</sup> helper T cell subsets<sup>18,32,39</sup>. Here we have described the epigenetic landscape of T<sub>H</sub>1- and T<sub>H</sub>17-related loci in  $\gamma\delta$  T cells freshly isolated from lymphoid organs. Through the use of genome-wide ChIP-seq analysis, we have identified many potential previously unknown participants in the differentiation and activation of  $\gamma\delta$  T cell subsets. Notably, among the top genes selected on the basis of their differences in histone H3 marking in  $\gamma\delta$ 27<sup>+</sup> versus  $\gamma\delta$ 27<sup>-</sup> T cell subsets, only a minority (40 of 120) were also different in CD4<sup>+</sup> T<sub>H</sub>1 versus T<sub>H</sub>17 subsets. This suggested that different lineage-specific mechanisms of differentiation might operate in  $\gamma\delta$  T cells, as exemplified by DKK3.

DKK3 is a secreted glycoprotein that modulates Wnt signaling and whose expression is often epigenetically silenced in a variety of cancer cell types, which suggests a potential role as a tumor suppressor<sup>40</sup>. Although little is known about the functions of DKK3 in the immune

system, it is reported to have a powerful regulatory function in CD8<sup>+</sup> T cells<sup>23</sup>. DKK3 is expressed in transgenic CD8<sup>+</sup> T cells tolerized in the neonatal period through interactions with a self antigen expressed in keratinocytes (in a double-transgenic mouse model) and is necessary and sufficient for maintenance of CD8<sup>+</sup> T cell tolerance in this model. In particular, *Dkk3*<sup>-/-</sup> mice reject autologous skin grafts and readily eradicate transplantable tumors<sup>23</sup>. Notably, published studies have suggested a general absence of *Dkk3* expression on T cell subsets, except for a specific subset of long-term memory CD8<sup>+</sup> T cells<sup>41</sup>. Our findings have extended *Dkk3* expression to the  $\gamma\delta 27^-$  T cell subset while excluding it from  $\gamma\delta 27^+$  T cells and CD4<sup>+</sup> helper T subsets. Furthermore, *Dkk3*<sup>-/-</sup>  $\gamma\delta 27^-$  T cell populations showed enrichment for cells that produced IL-17, which selectively linked DKK3 to the functional differentiation of this  $\gamma\delta$  T cell subset.

Although the mechanisms of action of DKK3 remain unclear, it is widely regarded as an inhibitor of the Wnt signaling cascade<sup>40</sup>. Notably, the downstream (transcriptional) effectors of Wnt signaling, TCF1 and Lef, have been shown to inhibit the differentiation of IL-17-producing  $\gamma\delta$  T cells<sup>42</sup>. Moreover, in our ChIP-seq analyses, *Tcf7* (which encodes TCF1) and *Lef* were biased toward  $\gamma\delta 27^+$  T cells (albeit below the eightfold threshold that was the inclusive criteria we used here): *Lef1* displayed a 6.4-fold enrichment for active H3K4me2 marks in  $\gamma\delta 27^+$  T cells and 4.8-fold enrichment for repressive H3K27me3 marks in  $\gamma\delta 27^-$  T cells; and *Tcf7* showed a 4.5-fold accumulation of H3K27me3 marks in  $\gamma\delta 27^-$  T cells. Given the increased production of IL-17 by *Dkk3*<sup>-/-</sup>  $\gamma\delta 27^-$  T cells, these data suggested crosstalk between DKK3 and Wnt signaling during the differentiation of  $\gamma\delta$  T cells that warrants further investigation.

As functional differentiation of  $\gamma\delta$  T cells can occur in the thymus<sup>10–12</sup>, the stability of cellular phenotypes in the periphery probably depends on the epigenetic patterning of key (master) transcription factors. Our data showed that *Tbx21* and *Eomes* (which encode T<sub>H</sub>1-related transcription factors) and *Rorc* and *Batf* (which encode T<sub>H</sub>17-related transcription factors) were distinctively patterned (by histone H3 modifications) in the  $\gamma\delta 27^+$  versus  $\gamma\delta 27^-$  subsets, and this was associated with their mRNA expression. Notably, genetic deletion of *Tbx21* or *Rorc* (data not shown) did not impair the epigenetic marking of the respective signature cytokine-encoding genes *Ifng* and *Il17*. That was consistent with studies showing that T-bet (encoded by *Tbx21*) has very modest effect on the active enhancer repertoire of CD4<sup>+</sup> T<sub>H</sub>1 cells<sup>43</sup>. That result notwithstanding, our data cannot exclude the possibility that histone patterning of *Ifng* or *Il17* in  $\gamma\delta$  T cell subsets is controlled by unknown combinations of T<sub>H</sub>1- or T<sub>H</sub>17-related transcriptional regulators. Of note, members of the STAT family of transcription factors have a critical role in shaping the epigenetic landscape of T<sub>H</sub>1, T<sub>H</sub>2 and T<sub>H</sub>17 cells<sup>18,43,44</sup>. Although the role of STAT1 and STAT4 in the differentiation of IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells requires further investigation, STAT3 is largely dispensable for the generation of IL-17-producing  $\gamma\delta$  T cells<sup>45</sup>. That is consistent with their independence of IL-6 signals<sup>46</sup> and illustrates how the developmental programming of  $\gamma\delta$  T cells (in the thymus) follows rules distinct from those of CD4<sup>+</sup> T cell differentiation after activation (by signaling via the T cell antigen receptor and cytokines) in the periphery.

While our study here concentrated on intracellular (nuclear) mechanisms of differentiation, it is also important to consider the roles of extracellular cues. In particular, the innate cytokines IL-1 $\beta$  and IL-23 drive the selective population expansion of IL-17<sup>+</sup>  $\gamma\delta$  T cells in infection<sup>20</sup>, autoimmunity<sup>1</sup> and tumor<sup>47</sup> models. Our data showed selective epigenetic and transcriptional polarization of IL-1R1 and IL-23R in  $\gamma\delta 27^-$  T cells, which highlights the importance

of these receptors in the biology of IL-17<sup>+</sup>  $\gamma\delta$  T cells (but not IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  T cells). IL-1 $\beta$  and IL-23 also seemed to be key elements of the inflammatory milieu that triggered the plasticity of  $\gamma\delta 27^-$  T cell *in vitro*. *In vivo*, we detected that plasticity in the tumor microenvironment but not during systemic responses to infection. Notably, CD4<sup>+</sup> T cells 'convert' from T<sub>H</sub>17 cells to T<sub>H</sub>1 cells under IL-23-dependent inflammatory conditions in experimental autoimmune encephalomyelitis but not during acute cutaneous infection with *Candida albicans*, while in the same conditions,  $\gamma\delta$  T cells remain producers of IL-17 and do not acquire IFN- $\gamma$  expression<sup>48</sup>. However, that does not indicate that microorganisms cannot trigger plasticity in  $\gamma\delta 27^-$  T cell, as it has been observed in gut-associated (mesenteric) lymph nodes after oral infection with *Listeria*<sup>49</sup>. Instead, we think this highlights the importance of the local inflammatory environment for the acquisition of IFN- $\gamma$  expression by  $\gamma\delta 27^-$  T cells.

The epigenomic data on  $\gamma\delta$  T cell subsets presented here provides a framework for the analysis and interpretation of the functions of  $\gamma\delta 27^+$  and  $\gamma\delta 27^-$  T cells in the periphery. In particular, we found that  $\gamma\delta 27^-$  T cells that acquired the ability to produce IL-17 during thymic development were nonetheless endowed with functional plasticity that allowed them to also produce IFN- $\gamma$  under local inflammatory conditions. Future studies should determine the specific roles of IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup>  $\gamma\delta$  cells *in vivo* models of infection, cancer or autoimmunity. These cells have been observed in the central nervous system of mice suffering experimental autoimmune encephalomyelitis (but not in healthy control mice)<sup>50</sup> and may thus contribute to the pathogenic role of  $\gamma\delta$  T cells in this<sup>1</sup> and other disease models.

## METHODS

Methods and any associated references are available in the [online version of the paper](#).

**Accession codes.** GEO: ChIP-seq data, [GSE42098](#).

*Note: Any Supplementary Information and Source Data files are available in the online version of the paper.*

## ACKNOWLEDGMENTS

We thank V. Benes for technical assistance with the ChIP-seq experiments; J. Ribot, S. de Almeida and N. Gonçalves-Sousa for technical advice; H. Kulbe, F. Balkwill and R. Thompson for help with the ID8 tumor model; M.J. Nunes and E. Rodrigues for help with ChIP procedures; and M. Soares, A. Vieira and S. Marques for help with cell sorting; A. Hayday, L. Lefrançois and M. Saraiva for discussions; B. Arnold and C. Niehrs (Deutsches Krebsforschungszentrum, Heidelberg) for *Dkk3*-deficient mice; C. Terhorst and B. van Driel (Harvard Medical School) for *Slamf1*-deficient mice; K. Roby (University of Kansas) for ID8 ovarian cancer cells; A. Pamplona (Instituto de Medicina Molecular) for *Plasmodium berghei* ANKA with transgenic expression of GFP; P. Simas (Instituto de Medicina Molecular) for murid herpes virus 4; M. Correia-Neves (Universidade do Minho) for *Mycobacterium avium* strain 244.; C. Reis e Sousa (The London Research Institute) for *Candida albicans* yeast strain WT-SC 3314; and the staff of the animal and flow cytometry facilities of our institutes for experimental assistance. Supported by the European Research Council (StG\_260352 to B.S.-S.), the Wellcome Trust (D.J.P.), the European Molecular Biology Organization (B.S.-S.), Fundação para a Ciência e Tecnologia (K.S., A.R.G. and M.R.) and the Graduate Program in Areas of Basic and Applied Biology of Universidade do Porto (M.R.).

## AUTHOR CONTRIBUTIONS

N.S. planned and did experiments in **Figures 1, 2, 4 and 5**; K.S. planned and did experiments in **Figures 3–6**; A.R.G. planned and did experiments in **Figures 1 and 2**; M.R. planned and did experiments in **Figure 6**; A.Q.G. planned and did experiments in **Figures 4 and 5**; D.J.P. contributed to designing the study and writing the manuscript; A.Q.G. helped to design and supervise the study; and B.S.-S. designed and supervised the study and wrote the manuscript.

## COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

1. Sutton, C.E. *et al.* Interleukin-1 and IL-23 induce innate IL-17 production from  $\gamma\delta$  T cells, amplifying Th17 responses and autoimmunity. *Immunity* **31**, 331–341 (2009).
2. Petermann, F. *et al.*  $\gamma\delta$  T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. *Immunity* **33**, 351–363 (2010).
3. Pantelyushin, S. *et al.* Roryt<sup>+</sup> innate lymphocytes and  $\gamma\delta$  T cells initiate psoriasisiform plaque formation in mice. *J. Clin. Invest.* **122**, 2252–2256 (2012).
4. Shichita, T. *et al.* Pivotal role of cerebral interleukin-17-producing  $\gamma\delta$  T cells in the delayed phase of ischemic brain injury. *Nat. Med.* **15**, 946–950 (2009).
5. Cai, Y. *et al.* Pivotal role of dermal IL-17-producing  $\gamma\delta$  T cells in skin inflammation. *Immunity* **35**, 596–610 (2011).
6. Lockhart, E., Green, A.M. & Flynn, J.L. IL-17 production is dominated by  $\gamma\delta$  T cells rather than CD4 T cells during *Mycobacterium tuberculosis* infection. *J. Immunol.* **177**, 4662–4669 (2006).
7. Bonneville, M., O'Brien, R.L. & Born, W.K.  $\gamma\delta$  T cell effector functions: a blend of innate programming and acquired plasticity. *Nat. Rev. Immunol.* **10**, 467–478 (2010).
8. Yin, Z. *et al.* T-Bet expression and failure of GATA-3 cross-regulation lead to default production of IFN- $\gamma$  by  $\gamma\delta$  T cells. *J. Immunol.* **168**, 1566–1571 (2002).
9. Gomes, A.Q., Martins, D.S. & Silva-Santos, B. Targeting  $\gamma\delta$  T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. *Cancer Res.* **70**, 10024–10027 (2010).
10. Ribot, J.C. *et al.* CD27 is a thymic determinant of the balance between interferon- $\gamma$ - and interleukin 17-producing  $\gamma\delta$  T cell subsets. *Nat. Immunol.* **10**, 427–436 (2009).
11. Jensen, K.D. *et al.* Thymic selection determines  $\gamma\delta$  T cell effector fate: antigen-naïve cells make interleukin-17 and antigen-experienced cells make interferon  $\gamma$ . *Immunity* **29**, 90–100 (2008).
12. Shibata, K. *et al.* Identification of CD25<sup>+</sup>  $\gamma\delta$  T cells as fetal thymus-derived naturally occurring IL-17 producers. *J. Immunol.* **181**, 5940–5947 (2008).
13. Haas, J.D. *et al.* CCR6 and NK1.1 distinguish between IL-17A and IFN- $\gamma$ -producing  $\gamma\delta$  effector T cells. *Eur. J. Immunol.* **39**, 3488–3497 (2009).
14. Martin, B., Hirota, K., Cua, D.J., Stockinger, B. & Veldhoen, M. Interleukin-17-producing  $\gamma\delta$  T cells selectively expand in response to pathogen products and environmental signals. *Immunity* **31**, 321–330 (2009).
15. Zhu, J., Yamane, H. & Paul, W.E. Differentiation of effector CD4 T cell populations. *Annu. Rev. Immunol.* **28**, 445–489 (2010).
16. Haas, J.D. *et al.* IL-17-mediated negative feedback restricts development of IL-17-producing  $\gamma\delta$  T cells to an embryonic wave. *Immunity* **37**, 48–59 (2012).
17. Narayan, K. *et al.* Intrathymic programming of effector fates in three molecularly distinct  $\gamma\delta$  T cell subtypes. *Nat. Immunol.* **13**, 511–518 (2012).
18. Wei, G. *et al.* Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4<sup>+</sup> T cells. *Immunity* **30**, 155–167 (2009).
19. Hirahara, K. *et al.* Helper T-cell differentiation and plasticity: insights from epigenetics. *Immunology* **134**, 235–245 (2011).
20. Ribot, J.C. *et al.* Cutting edge: adaptive versus innate receptor signals selectively control the pool sizes of murine IFN- $\gamma$ - or IL-17-producing  $\gamma\delta$  T cells upon infection. *J. Immunol.* **185**, 6421–6425 (2010).
21. Randall, K.L. *et al.* DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. *J. Exp. Med.* **208**, 2305–2320 (2011).
22. Jabara, H.H. *et al.* DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. *Nat. Immunol.* **13**, 612–620 (2012).
23. Papatriantafyllou, M. *et al.* Dickkopf-3, an immune modulator in peripheral CD8 T-cell tolerance. *Proc. Natl. Acad. Sci. USA* **109**, 1631–1636 (2012).
24. Griewank, K. *et al.* Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. *Immunity* **27**, 751–762 (2007).
25. van Driel, B. *et al.* Signaling lymphocyte activation molecule regulates development of colitis in mice. *Gastroenterology* **143**, 1544–1554 (2012).
26. Means, T.K. *et al.* Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. *J. Exp. Med.* **206**, 637–653 (2009).
27. Alfaro, D. *et al.* EphrinB1-EphB signaling regulates thymocyte-epithelium interactions involved in functional T cell development. *Eur. J. Immunol.* **37**, 2596–2605 (2007).
28. Basu, A. *et al.* Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO<sup>+</sup>CD4<sup>+</sup> T cells promotes Akt and ERK activation and costimulates IFN- $\gamma$  production. *J. Immunol.* **184**, 545–549 (2010).
29. Croft, M. Control of immunity by the TNFR-related molecule OX40 (CD134). *Annu. Rev. Immunol.* **28**, 57–78 (2010).
30. Furuichi, K. *et al.* Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. *J. Immunol.* **181**, 8670–8676 (2008).
31. Akimzhanov, A.M., Yang, X.O. & Dong, C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. *J. Biol. Chem.* **282**, 5969–5972 (2007).
32. Mukasa, R. *et al.* Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. *Immunity* **32**, 616–627 (2010).
33. Schoenborn, J.R. *et al.* Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon- $\gamma$ . *Nat. Immunol.* **8**, 732–742 (2007).
34. Wang, X. *et al.* Transcription of *il17* and *il17f* is controlled by conserved noncoding sequence 2. *Immunity* **36**, 23–31 (2012).
35. Turchinovich, G. & Hayday, A.C. Skint-1 identifies a common molecular mechanism for the development of interferon- $\gamma$ -secreting versus interleukin-17-secreting  $\gamma\delta$  T cells. *Immunity* **35**, 59–68 (2011).
36. Laird, R.M., Laky, K. & Hayes, S.M. Unexpected role for the B cell-specific Src family kinase B lymphoid kinase in the development of IL-17-producing  $\gamma\delta$  T cells. *J. Immunol.* **185**, 6518–6527 (2010).
37. de Almeida, S.F. *et al.* Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36. *Nat. Struct. Mol. Biol.* **18**, 977–983 (2011).
38. Charles, K.A. *et al.* The tumor-promoting actions of TNF- $\alpha$  involve TNFR1 and IL-17 in ovarian cancer in mice and humans. *J. Clin. Invest.* **119**, 3011–3023 (2009).
39. Lee, Y.K. *et al.* Late developmental plasticity in the T helper 17 lineage. *Immunity* **30**, 92–107 (2009).
40. Veeck, J. & Dahl, E. Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. *Biochim. Biophys. Acta* **1825**, 18–28 (2012).
41. Kaech, S.M., Hemby, S., Kersh, E. & Ahmed, R. Molecular and functional profiling of memory CD8 T cell differentiation. *Cell* **111**, 837–851 (2002).
42. Malhotra, N. *et al.* A network of high-mobility group box transcription factors programs innate interleukin-17 production. *Immunity* **38**, 681–693 (2013).
43. Vahedi, G. *et al.* STATs shape the active enhancer landscape of T cell populations. *Cell* **151**, 981–993 (2012).
44. Durant, L. *et al.* Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. *Immunity* **32**, 605–615 (2010).
45. Shibata, K. *et al.* Notch-Hes1 pathway is required for the development of IL-17-producing  $\gamma\delta$  T cells. *Blood* **118**, 586–593 (2011).
46. Lochner, M. *et al.* *In vivo* equilibrium of proinflammatory IL-17<sup>+</sup> and regulatory IL-10<sup>+</sup>Foxp3<sup>+</sup>ROR $\gamma$ t<sup>+</sup> T cells. *J. Exp. Med.* **205**, 1381–1393 (2008).
47. Carmi, Y. *et al.* Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. *J. Immunol.* **186**, 3462–3471 (2011).
48. Hirota, K. *et al.* Fate mapping of IL-17-producing T cells in inflammatory responses. *Nat. Immunol.* **12**, 255–263 (2011).
49. Sheridan, B.S. *et al.*  $\gamma\delta$  T cells exhibit multifunctional and protective memory in intestinal tissues. *Immunity* **39**, 184–195 (2013).
50. Reynolds, J.M., Martinez, G.J., Chung, Y. & Dong, C. Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. *Proc. Natl. Acad. Sci. USA* **109**, 13064–13069 (2012).





## ONLINE METHODS

**Mice.** All mice used were adults 6–12 weeks of age. *C57BL/6*, *Tcra*<sup>-/-</sup>, *Rorc*<sup>-/-</sup> and *Tbx21*<sup>-/-</sup> mice were from Jackson Laboratories. *Slamf1*<sup>-/-</sup> and *Dkk3*<sup>-/-</sup> mice were provided by C. Terhorst and B. Arnold, respectively. Mice were bred and maintained in the specific pathogen-free animal facilities of Instituto de Medicina Molecular (Lisbon, Portugal) or Queen Mary London University (London, UK). All experiments involving animals were done in compliance with the relevant laws and institutional guidelines and were approved by the ethics committees of Instituto de Medicina Molecular and Blizzard Institute.

**Cell sorting or analysis by flow cytometry.** For cell surface staining, single-cell suspensions were incubated for 15 min on ice with anti-FcγR (2.4G2; BD Pharmingen), and then for 30 min with saturating concentrations of the appropriate monoclonal antibody. The following monoclonal antibodies were used: eFluor 450–anti-CD4 (RM4-5), fluorescein isothiocyanate– or phycoerythrin–anti-TCRγδ (GL3), peridinin chlorophyll protein–cyanine 5.5–anti-CD3ε (145.2C11), phycoerythrin–indotricarbocyanine–anti-CD27 (LG.7F9), allophycocyanin–anti-CD25 (PC61 5.3), allophycocyanin–eFluor 780–anti-CD8 (53-6.7; all from eBiosciences); and Alexa Fluor 647–anti-CCR6 (29-2L17; BD Pharmingen). For sorting of T cell subsets, lymphoid organs were pooled from four mice (quantitative RT-PCR) or eight mice (ChIP-qPCR or ChIP-seq). Cells were sorted on FACSARIA III (BD Biosciences) or were analyzed on a FACSFortessa or FACSCalibur (BD Biosciences) and data were analyzed with FlowJo software (Tree Star).

For intracellular cytokine staining, cells sorted by flow cytometry were stimulated for 4 h at 37 °C with PMA (phorbol 12-myristate 13-acetate; 50 ng/mL) and ionomycin (1 μg/mL) (Sigma) with 10 μg/mL brefeldin A (Sigma) added during the final 2 h. Cells were stained (with antibodies identified above), fixed for 15 min at 4 °C with 2% paraformaldehyde, permeabilized for 30 min at room temperature with 0.5% saponin and 0.1% FCS in 2 mM EDTA–PBS in the presence of anti-FcγR (2.4G2; BD Pharmingen) and finally incubated for 1 h at room temperature with fluorescein isothiocyanate–anti-IL-17 (17B7; eBiosciences) and allophycocyanin–anti-IFN-γ (XMG1.2; eBiosciences).

**In vitro cell stimulation and polarization.** CD27<sup>+</sup> and CD27<sup>-</sup> γδ T cells were sorted by flow cytometry and subjected to various stimulation conditions for 48 h; CD4<sup>+</sup> T cell-polarization cultures were maintained for 6 d. For T<sub>H</sub>1 culture conditions, cells were activated with plate-bound monoclonal antibody (mAb) to CD3ε (5 μg/ml; 145.2C11; eBiosciences) and soluble mAb to CD28 (1 μg/ml; 37.51; eBiosciences), in the presence of IL-12 (5 ng/ml) and neutralizing mAb to IL-4 (10 μg/ml; 11B11; eBiosciences). For T<sub>H</sub>17 culture conditions, cells were activated with plate-bound anti-CD3ε, and soluble anti-CD28 and TGF-β (2 ng/ml), IL-1β (10 ng/ml), IL-6 (20 ng/ml), IL-21 (100 ng/ml), IL-23 (10 ng/ml) and neutralizing anti-IFN-γ (10 μg/ml) were added to the medium. Alternatively, cells were incubated on plate-bound mAb to CD3ε (5 μg/ml), in the presence or absence of mouse IL-7 (10 ng/ml) or IL-1β plus IL-23 (both at 10 ng/ml).

**ChIP-seq and ChIP-qPCR.** Cells were sorted by flow cytometry from the thymus or pooled spleen and lymph nodes for ChIP. The following antibodies were used: antibody to histone H3 (ab1791; Abcam), antibody to H3K36me3 (ab9050; Abcam), antibody to acetylated histone H3 (06-599; Millipore), antibody to H3K4me2 (07-030; Millipore) and antibody to H3K27me3 (07-449; Millipore).

Cells (1 × 10<sup>5</sup> to 1 × 10<sup>6</sup>) were crosslinked with formaldehyde and nuclei were isolated and sonicated with a Sanyo Soniprep 150 at an amplitude of 10 mm with 17 bursts of 10 s, which resulted in chromatin fragments 200–400 bp in length. Chromatin was immunoprecipitated as described<sup>51</sup>. The immunoprecipitated DNA released from crosslinked proteins was extracted with a QiaQuick kit in accordance with the manufacturer's instructions (Qiagen).

Deep sequencing was done at the GeneCore facility of the European Molecular Biology Laboratory. At least 1 ng of immunoprecipitated DNA was used for library preparation according to the Illumina protocol.

Alternatively, candidate genes were analyzed by ChIP-qPCR (primers, **Supplementary Table 3**).

The occupancy of the immunoprecipitated protein at each DNA site was estimated as follows:  $2^{(C_{\text{specific}} - C_{\text{totalH3}})}$  where,  $C_{\text{specific}}$  and  $C_{\text{totalH3}}$  are

threshold cycles of PCR of DNA from specific immunoprecipitation or total H3 immunoprecipitation, respectively.

**ChIP-seq data analysis.** High-throughput sequencing 'reads' were aligned to the reference mouse genome (the mm9 assembly of the National Center for Biotechnology Information) with Bowtie software for the alignment of short DNA sequences<sup>52</sup>. 'Read' quality was assessed with the FastQC quality-control tool for high throughput sequence data (Babraham Bioinformatics). 'Reads' with bad-quality scores, 'reads' not uniquely mapped and PCR duplicates (identical coordinates) were filtered out. The SAMtools utility for storing large nucleotide sequence alignments and manipulating alignments<sup>53</sup> and BEDtools software for the comparison of genomic features<sup>54</sup> were used for filtering steps and file format conversion. Three different peak-calling tools (MACS<sup>55,56</sup>, SICER<sup>57</sup> and RSEG<sup>58</sup>) were used for the detection of enrichment of histone modifications density. The recommended settings for histone modifications were used for these analyses, and only peaks that were consistently detected by the three methods were considered. Regions with different histone-modification densities in two samples were identified with the submodule of SICER<sup>57</sup>, with a false-discovery rate of 0.05 and absolute change in density >1.5-fold.

Regions with enrichment were then assigned to known genes of the UCSC Genome Browser, including a 1-kilobase region upstream of transcription start site (the mm9 assembly of the mouse genome of the National Center for Biotechnology Information)<sup>59</sup>.

For quantitative calculation and profiles of histone modifications for all genes, uniquely mapped 'reads' were extended in the 3' direction to reach 150 nt with the Pyicos deep-sequencing analysis tool<sup>60</sup>. Only 'read' counts that overlapped histone-enriched regions identified above were considered. The quantitative results per gene were log<sub>10</sub>-transformed. For genes without enriched regions, the amount was defined as 0.

For average profiles across genes with differences in histone densities, a 'metagene' profile was plotted for each gene group. Genes were aligned at the first and last nucleotides of the annotated transcripts and sequencing tags were scaled as follows: the 5' end (2 kb upstream of the transcription start site to 1 kb downstream) and the 3' end (500 bp upstream of the poly(A) site to 1 kb downstream) were unscaled and averaged in a 10-bp window, and the remainder of the gene was scaled to 200 bins of equal size so that all genes seem to have the same length (2 kb). Individual profiles were produced with a window of 5 bp. All profiles were plotted on a normalized reads-per-million basis. The processed data were plotted and visualized using software of the R project for statistical computing<sup>61</sup>.

**Real-time PCR.** Cell populations were sorted by flow cytometry and mRNA was prepared from those with a High Pure RNA Isolation kit (Roche). Random oligonucleotides (Invitrogen) and MMLV reverse transcriptase (Promega) were used for reverse transcription for 1 h at 42 °C. SYBR or TaqMan probe chemistry on an ABI ViiA7 cyclor (Applied Biosystems) was used for quantification of specific cDNA species relative to that of *Actb*. The cycling threshold ( $C_t$ ) for the target gene was subtracted from that of *Actb* and the relative amount was calculated as  $2^{-\Delta C_t}$ . Primers were designed with Primer Express software (Applied Biosystems) and their sequences were as follows: *Actb* forward, CGTGAAAAGATGACCCAGATCA, and reverse, TGGTACGACCAGAGGCATACAG; *Blk* forward, TTATGTGC CCAGCAACTTTGTG, and reverse, AAGGCACCTTTATTGCTCTCA CTCT; *Eomes* forward, CGTTCACCCAGAATCTCCTAACA, and reverse, TGCAGCCTCGGTTGGTATTT; *Hlx* forward, AGCTCCAACCAAGA AATTCTGT, and reverse, GCTTGTATGCTGTGGCATGGT; probe, ACA CATTCCAGGTCCCTATGCTGTGCTC; *Irfg* forward, TCTTCTTGG ATATCTGGAGGAAGT, and reverse, GAGATAATCTGGCTCTGCAG GATT; *Il17a* forward, CCAGAAGGCCCTCAGACTACCT, and reverse, TCCCTCCGATTGACACA; *Il17f* forward, CAACAAAACCAGGGCATT, and reverse, ACTGGGCTCAGCGATCTCT; *Il22* forward, GTGCCCTT CCTGACCAACT, and reverse, CTGTCTCCTCAGCCTTCTG; *Il23r* forward, TCAGTGCTACAATCTTCAGAGGACA, and reverse, GCCAA GAAGACCATTTCCCGA; *Maf* forward, AGCAGGTAGACCACCTCAA GCA, and reverse, GAGTCCCTTGGGTACATGAAAATT; *Rora* forward, TCCCCTACTGTTCCCTCACCAA, and reverse, GGAAGTCTGCCACG TTATCTG; *Rorc* forward, GTCCAGACAGCCACTGCATTC, and reverse,

TGCGCTGCCGTAGAAGGT; *Runx3* forward, ACTGGCGCTGCAACAA GAC, and reverse, GGCCCACGAATCGAAGGT; and *Tbx21* forward, CACACACGTCTTTACTTTCCAAGAGA, and reverse, CACTCGTATCAA CAGATGCGTACAT.

**Tumor transplantation.** ID8 ovarian cancer cells (provided by K. Roby) were injected intraperitoneally into C57BL/6 female mice ( $5 \times 10^6$  cells per mouse). Tumor growth was monitored as described<sup>38</sup>. Peritoneal exudate cells were collected 2–6 weeks after tumor transplantation, then were stimulated *in vitro* for 4 h with PMA and ionomycin and stained intracellularly for IL-17 and IFN- $\gamma$ .

**Infection.** Mice were infected intraperitoneally with  $1 \times 10^6$  red blood cells infected with *Plasmodium berghei* ANKA with transgenic expression of GFP (provided by A. Pamplona) and were monitored as previously described<sup>10</sup>. Cells from the spleen and lymph nodes were collected for analysis after 3 d.

Mice were infected intraperitoneally with  $1 \times 10^6$  plaque-forming units of murid herpes virus 4 (provided by P. Simas), and cells from the spleen and lymph nodes were collected after 14 d.

Mice were infected intravenously with  $1 \times 10^6$  colony-forming units of *Mycobacterium avium* strain 2447 (provided by M. Correia-Neves). Cells from the spleen and lymph nodes were collected 17 d after infection. Infection was confirmed by serial dilutions of homogenized spleen plated onto Middlebrook 7H10 agar.

Mice were infected intravenously with  $1 \times 10^5$  live *Candida albicans* yeast strain WT-SC 3314 (provided by C. Reis e Sousa). Cells from the spleen and lymph nodes were collected 7 d after infection. Infection was confirmed by

serial dilutions of homogenized kidney suspension plated onto yeast extract peptone dextrose agar medium.

**Statistical analysis.** A two-tailed non-parametric Mann-Whitney test was used for statistical analysis. *P* values of  $<0.05$  were considered significant.

51. Schnekenburger, M., Talaska, G. & Puga, A. Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation. *Mol. Cell. Biol.* **27**, 7089–7101 (2007).
52. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25–R35 (2009).
53. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
54. Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
55. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137–R146 (2008).
56. Feng, J., Liu, T. & Zhang, Y. Using MACS to identify peaks from ChIP-Seq data. *Curr Protoc Bioinformatics* **34**, 2.14.1–2.14.14 (2011).
57. Zang, C. *et al.* A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. *Bioinformatics* **25**, 1952–1958 (2009).
58. Song, Q. & Smith, A.D. Identifying dispersed epigenomic domains from ChIP-Seq data. *Bioinformatics* **27**, 870–871 (2011).
59. Rhead, B. *et al.* The UCSC Genome Browser database: update 2010. *Nucleic Acids Res.* **38**, D613–D619 (2010).
60. Althammer, S., Gonzalez-Vallinas, J., Ballare, C., Beato, M. & Eyras, E. Pyicos: a versatile toolkit for the analysis of high-throughput sequencing data. *Bioinformatics* **27**, 3333–3340 (2011).
61. R Core Team. *R: A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, Vienna, 2013).